Researchers have revealed new details about the CRISPR-Cas5-HNH/Cascade complex, a variant of the type I-E CRISPR-Cas system, ...

Rapidly add 300 μl of ice-cold nuclease S1 digestion buffer and immediately remove the tube from the water bath. Vortex gently to mix and then transfer the tube to a water bath set at the ...

The team observed a 4.4-fold increase in the editing efficiency of this modified nuclease, surpassing most of the commonly used RNA-guided endonucleases, including CjCas9. They called this variant ...

Newco Akribion Therapeutics GmbH has raised €8 million (US$8.3 million) in a seed round to develop a new and potent class of RNA-targeted CRISPR nucleases, which, rather than cleaving specific nucleic ...

For its wholly owned in vivo programs, Precision is developing an ARCUS nuclease that targets chronic hepatitis B covalently closed circular DNA. For its primary hyperoxaluria type 1 program ...

A study published in Nature Communications and conducted by researchers from the Institute of Physics of the Chinese Academy of Sciences revealed new ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

To uncover the mechanisms for nuclease regulation, we apply a multidisciplinary approach that includes hybrid structural biology, biochemistry, and cell biology. Together our work aims to understand ...

The traditional way of identifying nuclease activity, Fluorescence Resonance Energy Transfer (FRET) probe, costs 62 times more to produce than the Subak reporter. "Subak reporter is more cost ...

The platform enables direct, unbiased genome-wide identification and quantification of the exact position of double strand ...

Akribion Therapeutics ("Akribion"), the early-stage biotech developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announces its exit from stealth and the ...